Parkinson's disease dementia can be easily detected in routine clinical practice
Identifieur interne : 001C16 ( Istex/Corpus ); précédent : 001C15; suivant : 001C17Parkinson's disease dementia can be easily detected in routine clinical practice
Auteurs : Kathy Dujardin ; Bruno Dubois ; François Tison ; Franck Durif ; Isabelle Bourdeix ; Jean-Jacques Péré ; Alain DuhamelSource :
- Movement Disorders [ 0885-3185 ] ; 2010-12-15.
English descriptors
Abstract
Parkinson's disease (PD) is mainly characterized by its motor manifestations, but it is also frequently associated with dementia. Early diagnosis of PD dementia (PDD) is particularly important because effective cholinesterase inhibitor treatments are available. This study aimed at validating a short procedure for screening for PDD in routine clinical practice and which adopts recently published diagnostic criteria. One hundred eighty‐eight patients with PD participated in the study. The examination procedure comprised three steps: standard clinical examination, a short cognitive function assessment fulfilling the requirements of the Movement Disorders Society (Mini Mental State Examination, five‐word test, word generation task, and impact on daily life, including a questionnaire on compliance with medication) and an extensive evaluation of cognitive functions and behavior. After each step, the suspected presence or absence of dementia was recorded. After the short cognitive function assessment, PDD was suspected in 18.62% of the patients [95% confidence interval (CI): 13.32‐24.93%]. After the extensive assessment, 21.81% (95% CI: 16.13‐28.40%) met the criteria for probable PDD. The short battery's sensitivity and specificity were 65.85% (95% CI = 49.41‐79.92%) and 94.56% (95% CI = 89.56‐97.62%), respectively. A stepwise logistic regression analysis showed that use of a specific cut‐off considerably enhanced the short battery's sensitivity (85.37%, 95% CI = 70.83‐94.43%) without decreasing its specificity (83.67%, 95% CI = 76.69‐89.25%). With an easy‐to‐use, short battery of tests that are commonly used in routine clinical practice, it is possible to diagnose PDD in accordance with reference criteria and with the same sensitivity and specificity as in a more extensive evaluation. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23391
Links to Exploration step
ISTEX:0331D31BBB7888A23C31D510C88318366E08BAA5Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Parkinson's disease dementia can be easily detected in routine clinical practice</title><author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name><affiliation><mods:affiliation>Université Lille Nord de France, UDSL, CNRS FRE3291, Neurology and Movement Disorders Unit, Lille University Medical Center, Lille, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Neurologie et Pathologie du Mouvement, Neurologie A, Hôpital Salengro, Centre Hospitalier Universitaire, F‐59037 Lille cedex, France</mods:affiliation></affiliation></author><author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name><affiliation><mods:affiliation>INSERM‐UPMC UMRS 610, Federation of Neurology, AP‐HP, Salpêtrière Hospital; Université Paris 6, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="François" last="Tison">François Tison</name><affiliation><mods:affiliation>Department of Neurology, Bordeaux University Medical Center, Université de Bordeaux, Bordeaux, France</mods:affiliation></affiliation></author><author><name sortKey="Durif, Franck" sort="Durif, Franck" uniqKey="Durif F" first="Franck" last="Durif">Franck Durif</name><affiliation><mods:affiliation>Department of Neurology, Clermont‐Ferrand University Medical Center, Gabriel Montpied Hospital, Clermont‐Ferrand, France</mods:affiliation></affiliation></author><author><name sortKey="Bourdeix, Isabelle" sort="Bourdeix, Isabelle" uniqKey="Bourdeix I" first="Isabelle" last="Bourdeix">Isabelle Bourdeix</name><affiliation><mods:affiliation>Novartis Pharma SAS, Rueil‐Malmaison, France</mods:affiliation></affiliation></author><author><name sortKey="Pere, Jean Acques" sort="Pere, Jean Acques" uniqKey="Pere J" first="Jean-Jacques" last="Péré">Jean-Jacques Péré</name><affiliation><mods:affiliation>Novartis Pharma SAS, Rueil‐Malmaison, France</mods:affiliation></affiliation></author><author><name sortKey="Duhamel, Alain" sort="Duhamel, Alain" uniqKey="Duhamel A" first="Alain" last="Duhamel">Alain Duhamel</name><affiliation><mods:affiliation>Université Lille Nord de France, UDSL, EA2694, Biostatistics Department, Lille University Medical Center, Lille, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0331D31BBB7888A23C31D510C88318366E08BAA5</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23391</idno><idno type="url">https://api.istex.fr/document/0331D31BBB7888A23C31D510C88318366E08BAA5/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001C16</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001C16</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Parkinson's disease dementia can be easily detected in routine clinical practice</title><author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name><affiliation><mods:affiliation>Université Lille Nord de France, UDSL, CNRS FRE3291, Neurology and Movement Disorders Unit, Lille University Medical Center, Lille, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Neurologie et Pathologie du Mouvement, Neurologie A, Hôpital Salengro, Centre Hospitalier Universitaire, F‐59037 Lille cedex, France</mods:affiliation></affiliation></author><author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name><affiliation><mods:affiliation>INSERM‐UPMC UMRS 610, Federation of Neurology, AP‐HP, Salpêtrière Hospital; Université Paris 6, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="François" last="Tison">François Tison</name><affiliation><mods:affiliation>Department of Neurology, Bordeaux University Medical Center, Université de Bordeaux, Bordeaux, France</mods:affiliation></affiliation></author><author><name sortKey="Durif, Franck" sort="Durif, Franck" uniqKey="Durif F" first="Franck" last="Durif">Franck Durif</name><affiliation><mods:affiliation>Department of Neurology, Clermont‐Ferrand University Medical Center, Gabriel Montpied Hospital, Clermont‐Ferrand, France</mods:affiliation></affiliation></author><author><name sortKey="Bourdeix, Isabelle" sort="Bourdeix, Isabelle" uniqKey="Bourdeix I" first="Isabelle" last="Bourdeix">Isabelle Bourdeix</name><affiliation><mods:affiliation>Novartis Pharma SAS, Rueil‐Malmaison, France</mods:affiliation></affiliation></author><author><name sortKey="Pere, Jean Acques" sort="Pere, Jean Acques" uniqKey="Pere J" first="Jean-Jacques" last="Péré">Jean-Jacques Péré</name><affiliation><mods:affiliation>Novartis Pharma SAS, Rueil‐Malmaison, France</mods:affiliation></affiliation></author><author><name sortKey="Duhamel, Alain" sort="Duhamel, Alain" uniqKey="Duhamel A" first="Alain" last="Duhamel">Alain Duhamel</name><affiliation><mods:affiliation>Université Lille Nord de France, UDSL, EA2694, Biostatistics Department, Lille University Medical Center, Lille, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-12-15">2010-12-15</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">16</biblScope><biblScope unit="page" from="2769">2769</biblScope><biblScope unit="page" to="2776">2776</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">0331D31BBB7888A23C31D510C88318366E08BAA5</idno><idno type="DOI">10.1002/mds.23391</idno><idno type="ArticleID">MDS23391</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>basal ganglia</term><term>cognition</term><term>dementia</term><term>screening procedures</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease (PD) is mainly characterized by its motor manifestations, but it is also frequently associated with dementia. Early diagnosis of PD dementia (PDD) is particularly important because effective cholinesterase inhibitor treatments are available. This study aimed at validating a short procedure for screening for PDD in routine clinical practice and which adopts recently published diagnostic criteria. One hundred eighty‐eight patients with PD participated in the study. The examination procedure comprised three steps: standard clinical examination, a short cognitive function assessment fulfilling the requirements of the Movement Disorders Society (Mini Mental State Examination, five‐word test, word generation task, and impact on daily life, including a questionnaire on compliance with medication) and an extensive evaluation of cognitive functions and behavior. After each step, the suspected presence or absence of dementia was recorded. After the short cognitive function assessment, PDD was suspected in 18.62% of the patients [95% confidence interval (CI): 13.32‐24.93%]. After the extensive assessment, 21.81% (95% CI: 16.13‐28.40%) met the criteria for probable PDD. The short battery's sensitivity and specificity were 65.85% (95% CI = 49.41‐79.92%) and 94.56% (95% CI = 89.56‐97.62%), respectively. A stepwise logistic regression analysis showed that use of a specific cut‐off considerably enhanced the short battery's sensitivity (85.37%, 95% CI = 70.83‐94.43%) without decreasing its specificity (83.67%, 95% CI = 76.69‐89.25%). With an easy‐to‐use, short battery of tests that are commonly used in routine clinical practice, it is possible to diagnose PDD in accordance with reference criteria and with the same sensitivity and specificity as in a more extensive evaluation. © 2010 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Kathy Dujardin PhD</name><affiliations><json:string>Université Lille Nord de France, UDSL, CNRS FRE3291, Neurology and Movement Disorders Unit, Lille University Medical Center, Lille, France</json:string><json:string>Neurologie et Pathologie du Mouvement, Neurologie A, Hôpital Salengro, Centre Hospitalier Universitaire, F‐59037 Lille cedex, France</json:string></affiliations></json:item><json:item><name>Bruno Dubois MD</name><affiliations><json:string>INSERM‐UPMC UMRS 610, Federation of Neurology, AP‐HP, Salpêtrière Hospital; Université Paris 6, Paris, France</json:string></affiliations></json:item><json:item><name>François Tison MD</name><affiliations><json:string>Department of Neurology, Bordeaux University Medical Center, Université de Bordeaux, Bordeaux, France</json:string></affiliations></json:item><json:item><name>Franck Durif MD</name><affiliations><json:string>Department of Neurology, Clermont‐Ferrand University Medical Center, Gabriel Montpied Hospital, Clermont‐Ferrand, France</json:string></affiliations></json:item><json:item><name>Isabelle Bourdeix PhD</name><affiliations><json:string>Novartis Pharma SAS, Rueil‐Malmaison, France</json:string></affiliations></json:item><json:item><name>Jean‐Jacques Péré MD</name><affiliations><json:string>Novartis Pharma SAS, Rueil‐Malmaison, France</json:string></affiliations></json:item><json:item><name>Alain Duhamel PhD</name><affiliations><json:string>Université Lille Nord de France, UDSL, EA2694, Biostatistics Department, Lille University Medical Center, Lille, France</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dementia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>cognition</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>screening procedures</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>basal ganglia</value></json:item></subject><articleId><json:string>MDS23391</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Parkinson's disease (PD) is mainly characterized by its motor manifestations, but it is also frequently associated with dementia. Early diagnosis of PD dementia (PDD) is particularly important because effective cholinesterase inhibitor treatments are available. This study aimed at validating a short procedure for screening for PDD in routine clinical practice and which adopts recently published diagnostic criteria. One hundred eighty‐eight patients with PD participated in the study. The examination procedure comprised three steps: standard clinical examination, a short cognitive function assessment fulfilling the requirements of the Movement Disorders Society (Mini Mental State Examination, five‐word test, word generation task, and impact on daily life, including a questionnaire on compliance with medication) and an extensive evaluation of cognitive functions and behavior. After each step, the suspected presence or absence of dementia was recorded. After the short cognitive function assessment, PDD was suspected in 18.62% of the patients [95% confidence interval (CI): 13.32‐24.93%]. After the extensive assessment, 21.81% (95% CI: 16.13‐28.40%) met the criteria for probable PDD. The short battery's sensitivity and specificity were 65.85% (95% CI = 49.41‐79.92%) and 94.56% (95% CI = 89.56‐97.62%), respectively. A stepwise logistic regression analysis showed that use of a specific cut‐off considerably enhanced the short battery's sensitivity (85.37%, 95% CI = 70.83‐94.43%) without decreasing its specificity (83.67%, 95% CI = 76.69‐89.25%). With an easy‐to‐use, short battery of tests that are commonly used in routine clinical practice, it is possible to diagnose PDD in accordance with reference criteria and with the same sensitivity and specificity as in a more extensive evaluation. © 2010 Movement Disorder Society</abstract><qualityIndicators><score>7.904</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1842</abstractCharCount><pdfWordCount>4904</pdfWordCount><pdfCharCount>32440</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>259</abstractWordCount></qualityIndicators><title>Parkinson's disease dementia can be easily detected in routine clinical practice</title><corporate><json:item><name>for the EXECUTIVE study group</name></json:item></corporate><refBibs><json:item><author><json:item><name>MC de Rijk</name></json:item><json:item><name>LJ Launer</name></json:item><json:item><name>K Berger</name></json:item></author><host><volume>54</volume><pages><last>23</last><first>21</first></pages><issue>11 Suppl 5</issue><author></author><title>Neurology</title></host><title>Prevalence of Parkinson's disease in Europe: A collaborative study of population‐based cohorts. Neurologic Diseases in the Elderly Research Group</title></json:item><json:item><author><json:item><name>D Aarsland</name></json:item><json:item><name>K Andersen</name></json:item><json:item><name>JP Larsen</name></json:item><json:item><name>A Lolk</name></json:item><json:item><name>H Nielsen</name></json:item><json:item><name>P Kragh‐Sorensen</name></json:item></author><host><volume>56</volume><pages><last>736</last><first>730</first></pages><author></author><title>Neurology</title></host><title>Risk of dementia in Parkinson's disease: a community‐based, prospective study</title></json:item><json:item><author><json:item><name>D Aarsland</name></json:item><json:item><name>MW Kurz</name></json:item></author><host><volume>20</volume><pages><last>639</last><first>633</first></pages><author></author><title>Brain Pathol</title></host><title>The epidemiology of dementia associated with Parkinson's disease</title></json:item><json:item><author><json:item><name>TC Buter</name></json:item><json:item><name>A van den Hout</name></json:item><json:item><name>FE Matthews</name></json:item><json:item><name>JP Larsen</name></json:item><json:item><name>C Brayne</name></json:item><json:item><name>D Aarsland</name></json:item></author><host><volume>70</volume><pages><last>1022</last><first>1017</first></pages><author></author><title>Neurology</title></host><title>Dementia and survival in Parkinson disease: a 12‐year population study</title></json:item><json:item><author><json:item><name>D Aarsland</name></json:item><json:item><name>K Andersen</name></json:item><json:item><name>JP Larsen</name></json:item><json:item><name>A Lolk</name></json:item><json:item><name>P Kragh‐Sorensen</name></json:item></author><host><volume>60</volume><pages><last>392</last><first>387</first></pages><author></author><title>Arch Neurol</title></host><title>Prevalence and characteristics of dementia in Parkinson disease: an 8‐year prospective study</title></json:item><json:item><author><json:item><name>TA Hughes</name></json:item><json:item><name>HF Ross</name></json:item><json:item><name>S Musa</name></json:item></author><host><volume>54</volume><pages><last>1602</last><first>1596</first></pages><author></author><title>Neurology</title></host><title>A 10‐year study of the incidence of and factors predicting dementia in Parkinson's disease</title></json:item><json:item><author><json:item><name>P Martinez‐Martin</name></json:item><json:item><name>J Benito‐Leon</name></json:item><json:item><name>F Alonso</name></json:item></author><host><volume>14</volume><pages><last>472</last><first>463</first></pages><author></author><title>Qual Life Res</title></host><title>Quality of life of caregivers in Parkinson's disease</title></json:item><json:item><author><json:item><name>SA Parashos</name></json:item><json:item><name>DM Maraganore</name></json:item><json:item><name>PC O'Brien</name></json:item><json:item><name>WA Rocca</name></json:item></author><host><volume>77</volume><pages><last>925</last><first>918</first></pages><author></author><title>Mayo Clin Proc</title></host><title>Medical services utilization and prognosis in Parkinson disease: a population‐based study</title></json:item><json:item><author><json:item><name>M Emre</name></json:item><json:item><name>D Aarsland</name></json:item><json:item><name>A Albanese</name></json:item></author><host><volume>351</volume><pages><last>2518</last><first>2509</first></pages><author></author><title>The New England journal of medicine</title></host><title>Rivastigmine for dementia associated with Parkinson's disease</title></json:item><json:item><author><json:item><name>JT Olin</name></json:item><json:item><name>D Aarsland</name></json:item><json:item><name>X Meng</name></json:item></author><host><volume>29</volume><pages><last>515</last><first>510</first></pages><author></author><title>Dement Geriatr Cogn Disord</title></host><title>Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living</title></json:item><json:item><author><json:item><name>S Weintraub</name></json:item><json:item><name>MM Mesulam</name></json:item></author><host><pages><last>282</last><first>253</first></pages><author></author><title>Handbook of neuropsychology</title></host><title>Four neuropsychological profiles in dementia</title></json:item><json:item><author><json:item><name>K Bronnick</name></json:item><json:item><name>M Emre</name></json:item><json:item><name>R Lane</name></json:item><json:item><name>S Tekin</name></json:item><json:item><name>D Aarsland</name></json:item></author><host><volume>78</volume><pages><last>1068</last><first>1064</first></pages><author></author><title>J Neurol Neurosurg Psychiatry</title></host><title>Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease</title></json:item><json:item><author><json:item><name>W Poewe</name></json:item><json:item><name>S Gauthier</name></json:item><json:item><name>D Aarsland</name></json:item></author><host><volume>62</volume><pages><last>1587</last><first>1581</first></pages><author></author><title>Int J Clin Pract</title></host><title>Diagnosis and management of Parkinson's disease dementia</title></json:item><json:item><author><json:item><name>CC Janvin</name></json:item><json:item><name>JP Larsen</name></json:item><json:item><name>DP Salmon</name></json:item><json:item><name>D Galasko</name></json:item><json:item><name>K Hugdahl</name></json:item><json:item><name>D Aarsland</name></json:item></author><host><volume>21</volume><pages><last>342</last><first>337</first></pages><author></author><title>Mov Disord</title></host><title>Cognitive profiles of individual patients with Parkinson's disease and dementia: comparison with dementia with lewy bodies and Alzheimer's disease</title></json:item><json:item><author><json:item><name>M Emre</name></json:item><json:item><name>D Aarsland</name></json:item><json:item><name>R Brown</name></json:item></author><host><volume>22</volume><pages><last>1707</last><first>1689</first></pages><author></author><title>Mov Disord</title></host><title>Clinical diagnostic criteria for dementia associated with Parkinson's disease</title></json:item><json:item><author><json:item><name>B Dubois</name></json:item><json:item><name>D Burn</name></json:item><json:item><name>C Goetz</name></json:item></author><host><volume>22</volume><pages><last>2324</last><first>2314</first></pages><author></author><title>Mov Disord</title></host><title>Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force</title></json:item><json:item><author><json:item><name>DJ Gelb</name></json:item><json:item><name>E Oliver</name></json:item><json:item><name>S Gilman</name></json:item></author><host><volume>56</volume><pages><last>39</last><first>33</first></pages><author></author><title>Arch Neurol</title></host><title>Diagnostic criteria for Parkinson disease</title></json:item><json:item><author><json:item><name>MM Hoehn</name></json:item><json:item><name>MD Yahr</name></json:item></author><host><volume>50</volume><pages><first>318</first></pages><author></author><title>Neurol</title></host><title>Parkinsonism: onset, progression, and mortality. 1967</title></json:item><json:item><author><json:item><name>P Cowppli‐Bony</name></json:item><json:item><name>C Fabrigoule</name></json:item><json:item><name>L Letenneur</name></json:item></author><host><volume>161</volume><pages><last>1212</last><first>1205</first></pages><issue>12 Pt 1</issue><author></author><title>Rev Neurol (Paris)</title></host><title>[Validity of the five‐word screening test for Alzheimer's disease in a population based study]</title></json:item><json:item><author><json:item><name>CG Goetz</name></json:item><json:item><name>M Emre</name></json:item><json:item><name>B Dubois</name></json:item></author><host><volume>64</volume><pages><last>92</last><first>81</first></pages><issue>Suppl 2</issue><author></author><title>Ann Neurol</title></host><title>Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis</title></json:item><json:item><author><json:item><name>S Mattis</name></json:item></author><host><pages><last>121</last><first>77</first></pages><author></author><title>Geriatric psychiatry</title></host><title>Mental status examination for organic mental syndrome in the elderly patient</title></json:item><json:item><author><json:item><name>M Van der Linden</name></json:item><json:item><name>F Coyette</name></json:item><json:item><name>J Poitrenaud</name></json:item></author><host><pages><last>47</last><first>25</first></pages><author></author><title>L'évaluation des troubles de la mémoire</title></host><title>L'épreuve de rappel libre/rappel indicé à 16 items (RL/RI‐16)</title></json:item><json:item><author><json:item><name>B Dubois</name></json:item><json:item><name>A Slachevsky</name></json:item><json:item><name>I Litvan</name></json:item><json:item><name>B Pillon</name></json:item></author><host><volume>55</volume><pages><last>1626</last><first>1621</first></pages><author></author><title>Neurology</title></host><title>The FAB: a Frontal Assessment Battery at bedside</title></json:item><json:item><host><author></author><title>Kaplan E,Goodglass H,Weintraub S.Boston naming test.Boston:Aphasia Research Center, Boston University;1976.</title></host></json:item><json:item><author><json:item><name>DR Royall</name></json:item><json:item><name>RK Mahurin</name></json:item><json:item><name>KF Gray</name></json:item></author><host><volume>40</volume><pages><last>1226</last><first>1221</first></pages><author></author><title>J Am Geriatr Soc</title></host><title>Bedside assessment of executive cognitive impairment: the executive interview</title></json:item><json:item><host><author></author><title>James M,Warrington, E.K.VOSP—visual object and space perception battery.Bury St Edmunds:Thames Valley Test Company;1991.</title></host></json:item><json:item><author><json:item><name>SA Montgomery</name></json:item><json:item><name>M Asberg</name></json:item></author><host><volume>134</volume><pages><last>389</last><first>382</first></pages><author></author><title>Br J Psychiatry</title></host><title>A new depression scale designed to be sensitive to change</title></json:item><json:item><author><json:item><name>P Sockeel</name></json:item><json:item><name>K Dujardin</name></json:item><json:item><name>D Devos</name></json:item><json:item><name>C Deneve</name></json:item><json:item><name>A Destee</name></json:item><json:item><name>L Defebvre</name></json:item></author><host><volume>77</volume><pages><last>584</last><first>579</first></pages><author></author><title>J Neurol Neurosurg Psychiatry</title></host><title>The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson's disease</title></json:item><json:item><author><json:item><name>JL Cummings</name></json:item><json:item><name>M Mega</name></json:item><json:item><name>K Gray</name></json:item><json:item><name>S Rosenberg‐Thompson</name></json:item><json:item><name>DA Carusi</name></json:item><json:item><name>J Gornbein</name></json:item></author><host><volume>44</volume><pages><last>2314</last><first>2308</first></pages><author></author><title>Neurology</title></host><title>The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia</title></json:item><json:item><author><json:item><name>W Sauerbrei</name></json:item></author><host><volume>48</volume><pages><last>329</last><first>313</first></pages><author></author><title>Appl Stat</title></host><title>The use of resampling methods to simplify regression models in medical statistics</title></json:item><json:item><author><json:item><name>C Zadikoff</name></json:item><json:item><name>SH Fox</name></json:item><json:item><name>DF Tang‐Wai</name></json:item></author><host><volume>23</volume><pages><last>299</last><first>297</first></pages><author></author><title>Mov Disord</title></host><title>A comparison of the mini mental state exam to the montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease</title></json:item><json:item><author><json:item><name>RJ Athey</name></json:item><json:item><name>RW Walker</name></json:item></author><host><volume>21</volume><pages><last>982</last><first>977</first></pages><author></author><title>Int J Geriatr Psychiatry</title></host><title>Demonstration of cognitive decline in Parkinson's disease using the Cambridge Cognitive Assessment (Revised) (CAMCOG‐R)</title></json:item><json:item><author><json:item><name>S Hoops</name></json:item><json:item><name>S Nazem</name></json:item><json:item><name>AD Siderowf</name></json:item></author><host><volume>73</volume><pages><last>1745</last><first>1738</first></pages><author></author><title>Neurology</title></host><title>Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease</title></json:item><json:item><author><json:item><name>TH Bak</name></json:item><json:item><name>TT Rogers</name></json:item><json:item><name>LM Crawford</name></json:item><json:item><name>VC Hearn</name></json:item><json:item><name>PS Mathuranath</name></json:item><json:item><name>JR Hodges</name></json:item></author><host><volume>76</volume><pages><last>422</last><first>420</first></pages><author></author><title>J Neurol Neurosurg Psychiatry</title></host><title>Cognitive bedside assessment in atypical parkinsonian syndromes</title></json:item><json:item><author><json:item><name>S Nazem</name></json:item><json:item><name>AD Siderowf</name></json:item><json:item><name>JE Duda</name></json:item></author><host><volume>57</volume><pages><last>308</last><first>304</first></pages><author></author><title>J Am Geriatr Soc</title></host><title>Montreal cognitive assessment performance in patients with Parkinson's disease with “normal” global cognition according to mini‐mental state examination score</title></json:item><json:item><author><json:item><name>D Aarsland</name></json:item><json:item><name>J Zaccai</name></json:item><json:item><name>C Brayne</name></json:item></author><host><volume>20</volume><pages><last>1263</last><first>1255</first></pages><author></author><title>Mov Disord</title></host><title>A systematic review of prevalence studies of dementia in Parkinson's disease</title></json:item><json:item><author><json:item><name>D Aarsland</name></json:item><json:item><name>K Bronnick</name></json:item><json:item><name>U Ehrt</name></json:item></author><host><volume>78</volume><pages><last>42</last><first>36</first></pages><author></author><title>J Neurol Neurosurg Psychiatry</title></host><title>Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress</title></json:item><json:item><author><json:item><name>CB Hall</name></json:item><json:item><name>C Derby</name></json:item><json:item><name>A LeValley</name></json:item><json:item><name>MJ Katz</name></json:item><json:item><name>J Verghese</name></json:item><json:item><name>RB Lipton</name></json:item></author><host><volume>69</volume><pages><last>1664</last><first>1657</first></pages><author></author><title>Neurology</title></host><title>Education delays accelerated decline on a memory test in persons who develop dementia</title></json:item></refBibs><genre><json:string>article</json:string></genre><host><volume>25</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>8</total><last>2776</last><first>2769</first></pages><issn><json:string>0885-3185</json:string></issn><issue>16</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><categories><wos><json:string>science</json:string><json:string>clinical neurology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>neurology & neurosurgery</json:string></scienceMetrix></categories><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/mds.23391</json:string></doi><id>0331D31BBB7888A23C31D510C88318366E08BAA5</id><score>0.25936222</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/0331D31BBB7888A23C31D510C88318366E08BAA5/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/0331D31BBB7888A23C31D510C88318366E08BAA5/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/0331D31BBB7888A23C31D510C88318366E08BAA5/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Parkinson's disease dementia can be easily detected in routine clinical practice</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Copyright © 2010 Movement Disorder Society</p></availability><date>2010</date></publicationStmt><notesStmt><note type="content">*K.D. and B.D. contributed equally to this work.</note><note type="content">*Potential conflict of interest: None.</note><note type="content">*Members of the “Executive study group” are listed as an Appendix.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Parkinson's disease dementia can be easily detected in routine clinical practice</title><author><orgName>for the EXECUTIVE study group</orgName></author><author xml:id="author-1"><persName><forename type="first">Kathy</forename><surname>Dujardin</surname></persName><roleName type="degree">PhD</roleName><affiliation>Université Lille Nord de France, UDSL, CNRS FRE3291, Neurology and Movement Disorders Unit, Lille University Medical Center, Lille, France</affiliation><affiliation>Neurologie et Pathologie du Mouvement, Neurologie A, Hôpital Salengro, Centre Hospitalier Universitaire, F‐59037 Lille cedex, France</affiliation></author><author xml:id="author-2"><persName><forename type="first">Bruno</forename><surname>Dubois</surname></persName><roleName type="degree">MD</roleName><note type="biography">K.D. and B.D. contributed equally to this work.</note><affiliation>K.D. and B.D. contributed equally to this work.</affiliation><affiliation>INSERM‐UPMC UMRS 610, Federation of Neurology, AP‐HP, Salpêtrière Hospital; Université Paris 6, Paris, France</affiliation></author><author xml:id="author-3"><persName><forename type="first">François</forename><surname>Tison</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Bordeaux University Medical Center, Université de Bordeaux, Bordeaux, France</affiliation></author><author xml:id="author-4"><persName><forename type="first">Franck</forename><surname>Durif</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Clermont‐Ferrand University Medical Center, Gabriel Montpied Hospital, Clermont‐Ferrand, France</affiliation></author><author xml:id="author-5"><persName><forename type="first">Isabelle</forename><surname>Bourdeix</surname></persName><roleName type="degree">PhD</roleName><affiliation>Novartis Pharma SAS, Rueil‐Malmaison, France</affiliation></author><author xml:id="author-6"><persName><forename type="first">Jean‐Jacques</forename><surname>Péré</surname></persName><roleName type="degree">MD</roleName><affiliation>Novartis Pharma SAS, Rueil‐Malmaison, France</affiliation></author><author xml:id="author-7"><persName><forename type="first">Alain</forename><surname>Duhamel</surname></persName><roleName type="degree">PhD</roleName><affiliation>Université Lille Nord de France, UDSL, EA2694, Biostatistics Department, Lille University Medical Center, Lille, France</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-12-15"></date><biblScope unit="volume">25</biblScope><biblScope unit="issue">16</biblScope><biblScope unit="page" from="2769">2769</biblScope><biblScope unit="page" to="2776">2776</biblScope></imprint></monogr><idno type="istex">0331D31BBB7888A23C31D510C88318366E08BAA5</idno><idno type="DOI">10.1002/mds.23391</idno><idno type="ArticleID">MDS23391</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Parkinson's disease (PD) is mainly characterized by its motor manifestations, but it is also frequently associated with dementia. Early diagnosis of PD dementia (PDD) is particularly important because effective cholinesterase inhibitor treatments are available. This study aimed at validating a short procedure for screening for PDD in routine clinical practice and which adopts recently published diagnostic criteria. One hundred eighty‐eight patients with PD participated in the study. The examination procedure comprised three steps: standard clinical examination, a short cognitive function assessment fulfilling the requirements of the Movement Disorders Society (Mini Mental State Examination, five‐word test, word generation task, and impact on daily life, including a questionnaire on compliance with medication) and an extensive evaluation of cognitive functions and behavior. After each step, the suspected presence or absence of dementia was recorded. After the short cognitive function assessment, PDD was suspected in 18.62% of the patients [95% confidence interval (CI): 13.32‐24.93%]. After the extensive assessment, 21.81% (95% CI: 16.13‐28.40%) met the criteria for probable PDD. The short battery's sensitivity and specificity were 65.85% (95% CI = 49.41‐79.92%) and 94.56% (95% CI = 89.56‐97.62%), respectively. A stepwise logistic regression analysis showed that use of a specific cut‐off considerably enhanced the short battery's sensitivity (85.37%, 95% CI = 70.83‐94.43%) without decreasing its specificity (83.67%, 95% CI = 76.69‐89.25%). With an easy‐to‐use, short battery of tests that are commonly used in routine clinical practice, it is possible to diagnose PDD in accordance with reference criteria and with the same sensitivity and specificity as in a more extensive evaluation. © 2010 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>Parkinson's disease</term></item><item><term>dementia</term></item><item><term>cognition</term></item><item><term>screening procedures</term></item><item><term>basal ganglia</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-06-04">Received</change><change when="2010-07-14">Registration</change><change when="2010-12-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/0331D31BBB7888A23C31D510C88318366E08BAA5/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="160"><doi origin="wiley" registered="yes">10.1002/mds.v25.16</doi><numberingGroup><numbering type="journalVolume" number="25">25</numbering><numbering type="journalIssue">16</numbering></numberingGroup><coverDate startDate="2010-12-15">15 December 2010</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="110" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23391</doi><idGroup><id type="unit" value="MDS23391"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2010 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2010-06-04"></event><event type="manuscriptRevised" date="2010-07-01"></event><event type="manuscriptAccepted" date="2010-07-14"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4 mode:FullText" date="2010-12-16"></event><event type="publishedOnlineEarlyUnpaginated" date="2010-10-05"></event><event type="firstOnline" date="2010-10-05"></event><event type="publishedOnlineFinalForm" date="2010-12-16"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">2769</numbering><numbering type="pageLast">2776</numbering></numberingGroup><correspondenceTo>Neurologie et Pathologie du Mouvement, Neurologie A, Hôpital Salengro, Centre Hospitalier Universitaire, F‐59037 Lille cedex, France</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23391.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="4"></count><count type="referenceTotal" number="38"></count><count type="wordTotal" number="6239"></count></countGroup><titleGroup><title type="main" xml:lang="en">Parkinson's disease dementia can be easily detected in routine clinical practice<link href="#fn1"></link><link href="#fn2"></link><link href="#fn3"></link></title><title type="short" xml:lang="en">Screening for Parkinson's Disease Dementia</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Kathy</givenNames><familyName>Dujardin</familyName><degrees>PhD</degrees></personName><contactDetails><email normalForm="kathy.dujardin@chru-lille.fr">kathy.dujardin@chru‐lille.fr</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2" noteRef="#fn1"><personName><givenNames>Bruno</givenNames><familyName>Dubois</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>François</givenNames><familyName>Tison</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Franck</givenNames><familyName>Durif</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Isabelle</givenNames><familyName>Bourdeix</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Jean‐Jacques</givenNames><familyName>Péré</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Alain</givenNames><familyName>Duhamel</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af6"><groupName>for the EXECUTIVE study group</groupName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>Université Lille Nord de France, UDSL, CNRS FRE3291, Neurology and Movement Disorders Unit, Lille University Medical Center, Lille, France</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>INSERM‐UPMC UMRS 610, Federation of Neurology, AP‐HP, Salpêtrière Hospital; Université Paris 6, Paris, France</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="FR" type="organization"><unparsedAffiliation>Department of Neurology, Bordeaux University Medical Center, Université de Bordeaux, Bordeaux, France</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="FR" type="organization"><unparsedAffiliation>Department of Neurology, Clermont‐Ferrand University Medical Center, Gabriel Montpied Hospital, Clermont‐Ferrand, France</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="FR" type="organization"><unparsedAffiliation>Novartis Pharma SAS, Rueil‐Malmaison, France</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="FR" type="organization"><unparsedAffiliation>Université Lille Nord de France, UDSL, EA2694, Biostatistics Department, Lille University Medical Center, Lille, France</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">dementia</keyword><keyword xml:id="kwd3">cognition</keyword><keyword xml:id="kwd4">screening procedures</keyword><keyword xml:id="kwd5">basal ganglia</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Parkinson's disease (PD) is mainly characterized by its motor manifestations, but it is also frequently associated with dementia. Early diagnosis of PD dementia (PDD) is particularly important because effective cholinesterase inhibitor treatments are available. This study aimed at validating a short procedure for screening for PDD in routine clinical practice and which adopts recently published diagnostic criteria. One hundred eighty‐eight patients with PD participated in the study. The examination procedure comprised three steps: standard clinical examination, a short cognitive function assessment fulfilling the requirements of the Movement Disorders Society (Mini Mental State Examination, five‐word test, word generation task, and impact on daily life, including a questionnaire on compliance with medication) and an extensive evaluation of cognitive functions and behavior. After each step, the suspected presence or absence of dementia was recorded. After the short cognitive function assessment, PDD was suspected in 18.62% of the patients [95% confidence interval (CI): 13.32‐24.93%]. After the extensive assessment, 21.81% (95% CI: 16.13‐28.40%) met the criteria for probable PDD. The short battery's sensitivity and specificity were 65.85% (95% CI = 49.41‐79.92%) and 94.56% (95% CI = 89.56‐97.62%), respectively. A stepwise logistic regression analysis showed that use of a specific cut‐off considerably enhanced the short battery's sensitivity (85.37%, 95% CI = 70.83‐94.43%) without decreasing its specificity (83.67%, 95% CI = 76.69‐89.25%). With an easy‐to‐use, short battery of tests that are commonly used in routine clinical practice, it is possible to diagnose PDD in accordance with reference criteria and with the same sensitivity and specificity as in a more extensive evaluation. © 2010 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>K.D. and B.D. contributed equally to this work.</p></note><note xml:id="fn2"><p>Potential conflict of interest: None.</p></note><note xml:id="fn3"><p>Members of the “Executive study group” are listed as an Appendix.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Parkinson's disease dementia can be easily detected in routine clinical practice</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Screening for Parkinson's Disease Dementia</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Parkinson's disease dementia can be easily detected in routine clinical practice</title></titleInfo><name type="personal"><namePart type="given">Kathy</namePart><namePart type="family">Dujardin</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Université Lille Nord de France, UDSL, CNRS FRE3291, Neurology and Movement Disorders Unit, Lille University Medical Center, Lille, France</affiliation><affiliation>Neurologie et Pathologie du Mouvement, Neurologie A, Hôpital Salengro, Centre Hospitalier Universitaire, F‐59037 Lille cedex, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Bruno</namePart><namePart type="family">Dubois</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>INSERM‐UPMC UMRS 610, Federation of Neurology, AP‐HP, Salpêtrière Hospital; Université Paris 6, Paris, France</affiliation><description>K.D. and B.D. contributed equally to this work.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">François</namePart><namePart type="family">Tison</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Bordeaux University Medical Center, Université de Bordeaux, Bordeaux, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Franck</namePart><namePart type="family">Durif</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Clermont‐Ferrand University Medical Center, Gabriel Montpied Hospital, Clermont‐Ferrand, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Isabelle</namePart><namePart type="family">Bourdeix</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Novartis Pharma SAS, Rueil‐Malmaison, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jean‐Jacques</namePart><namePart type="family">Péré</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Novartis Pharma SAS, Rueil‐Malmaison, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alain</namePart><namePart type="family">Duhamel</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Université Lille Nord de France, UDSL, EA2694, Biostatistics Department, Lille University Medical Center, Lille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="corporate"><namePart>for the EXECUTIVE study group</namePart><description>Université Lille Nord de France, UDSL, CNRS FRE3291, Neurology and Movement Disorders Unit, Lille University Medical Center, Lille, FranceINSERM‐UPMC UMRS 610, Federation of Neurology, AP‐HP, Salpêtrière Hospital; Université Paris 6, Paris, FranceDepartment of Neurology, Bordeaux University Medical Center, Université de Bordeaux, Bordeaux, FranceDepartment of Neurology, Clermont‐Ferrand University Medical Center, Gabriel Montpied Hospital, Clermont‐Ferrand, FranceNovartis Pharma SAS, Rueil‐Malmaison, FranceUniversité Lille Nord de France, UDSL, EA2694, Biostatistics Department, Lille University Medical Center, Lille, France</description></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2010-12-15</dateIssued><dateCaptured encoding="w3cdtf">2010-06-04</dateCaptured><dateValid encoding="w3cdtf">2010-07-14</dateValid><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">4</extent><extent unit="references">38</extent><extent unit="words">6239</extent></physicalDescription><abstract lang="en">Parkinson's disease (PD) is mainly characterized by its motor manifestations, but it is also frequently associated with dementia. Early diagnosis of PD dementia (PDD) is particularly important because effective cholinesterase inhibitor treatments are available. This study aimed at validating a short procedure for screening for PDD in routine clinical practice and which adopts recently published diagnostic criteria. One hundred eighty‐eight patients with PD participated in the study. The examination procedure comprised three steps: standard clinical examination, a short cognitive function assessment fulfilling the requirements of the Movement Disorders Society (Mini Mental State Examination, five‐word test, word generation task, and impact on daily life, including a questionnaire on compliance with medication) and an extensive evaluation of cognitive functions and behavior. After each step, the suspected presence or absence of dementia was recorded. After the short cognitive function assessment, PDD was suspected in 18.62% of the patients [95% confidence interval (CI): 13.32‐24.93%]. After the extensive assessment, 21.81% (95% CI: 16.13‐28.40%) met the criteria for probable PDD. The short battery's sensitivity and specificity were 65.85% (95% CI = 49.41‐79.92%) and 94.56% (95% CI = 89.56‐97.62%), respectively. A stepwise logistic regression analysis showed that use of a specific cut‐off considerably enhanced the short battery's sensitivity (85.37%, 95% CI = 70.83‐94.43%) without decreasing its specificity (83.67%, 95% CI = 76.69‐89.25%). With an easy‐to‐use, short battery of tests that are commonly used in routine clinical practice, it is possible to diagnose PDD in accordance with reference criteria and with the same sensitivity and specificity as in a more extensive evaluation. © 2010 Movement Disorder Society</abstract><note type="content">*K.D. and B.D. contributed equally to this work.</note><note type="content">*Potential conflict of interest: None.</note><note type="content">*Members of the “Executive study group” are listed as an Appendix.</note><subject lang="en"><genre>keywords</genre><topic>Parkinson's disease</topic><topic>dementia</topic><topic>cognition</topic><topic>screening procedures</topic><topic>basal ganglia</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="journal">journal</genre><subject><genre>article-category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>16</number></detail><extent unit="pages"><start>2769</start><end>2776</end><total>8</total></extent></part></relatedItem><identifier type="istex">0331D31BBB7888A23C31D510C88318366E08BAA5</identifier><identifier type="DOI">10.1002/mds.23391</identifier><identifier type="ArticleID">MDS23391</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2010 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C16 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001C16 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:0331D31BBB7888A23C31D510C88318366E08BAA5
|texte= Parkinson's disease dementia can be easily detected in routine clinical practice
}}
| This area was generated with Dilib version V0.6.29. |  |